Send me real-time posts from this site at my email

Why Gossamer Bio Stock Is Tumbling Today

What happened

Shares of Gossamer Bio (NASDAQ: GOSS) were tumbling 16.4% lower as of 11:55 a.m. EDT on Tuesday. The decline came after the company announced the pricing of a secondary stock offering of more than 9.4 million shares and $200 million in convertible senior notes due in 2027. Gossamer plans to offer the additional stock at a price of $13.25 per share.

So what

Secondary stock offerings are common occurrences for small biotechs like Gossamer. But they come with a major downside for the biotech stocks: the dilution in the value of existing shares.

Image source: Getty Images.

The pricing of Gossamer's secondary offering and convertible senior notes is nearly 12% below the stock's closing price on Monday. The addition of more than 9.4 million new shares represents around 14% of its current outstanding shares. However, Gossamer also will allow the underwriters of the secondary offering to purchase another 1.4 million or so shares under the same terms. These additional shares bump up the dilution of the biotech's outstanding shares to around 16%, which not-so-coincidently is roughly in line with today's decline in Gossamer's share price.

Investors should also note the good news with Gossamer's secondary offering and issuance of convertible senior notes. The company expects to raise around $325 million in gross proceeds. Gossamer plans to use its additional cash to fund research and development, advance its development programs, and for working capital and general corporate purposes.

Now what

Gossamer's offerings are expected to close on Thursday of this week. The company should have another key piece of news on the way. Gossamer anticipates reporting top-line data in the second half of 2020 from its phase 2 clinical study evaluating GB001 in treating chronic rhinosinusitis.

10 stocks we like better than Gossamer Bio
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gossamer Bio wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of April 16, 2020

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue